Liposome/gold hybrid nanoparticle encoded with CoQ10 (LGNP-CoQ10) suppressed rheumatoid arthritis via STAT3/Th17 targeting.

Coenzyme Q10 (CoQ10), also known as ubiquinone, is a fat-soluble antioxidant. Although CoQ10 has not been approved as medication by the Food and Drug Administration, it is widely used in dietary supplements. Some studies have shown that CoQ10 has anti-inflammatory effects on various autoimmune disorders. In this study, we investigated the anti-inflammatory effects of liposome/gold hybrid nanoparticles encoded with CoQ10 (LGNP-CoQ10). Both CoQ10 and LGNP-CoQ10 were administered orally to mice with collagen-induced arthritis (CIA) for 10 weeks. The inflammation pathology of joint tissues of CIA mice was then analyzed using hematoxylin and eosin and Safranin O staining, as well as immunohistochemistry analysis. We obtained immunofluorescence staining images of spleen tissues using confocal microscopy. We found that pro-inflammatory cytokines were significantly decreased in LGNP-CoQ10 injected mice. Th17 cell and phosphorylated STAT3-expressed cell populations were also decreased in LGNP-CoQ10 injected mice. When human peripheral blood mononuclear cells (PBMCs) were treated with CoQ10 and LGNP-CoQ10, the IL-17 expression of PBMCs in the LGNP-CoQ10-treated group was significantly reduced. Together, these results suggest that LGNP-CoQ10 has therapeutic potential for the treatment of rheumatoid arthritis.

1. Introduction

Rheumatoid arthritis (RA) is an autoimmune disorder that causes long-term and systemic joint inflammation [1]. RA has been reported to lead to bone erosion and cartilage destruction [2]. Although the precise mechanism of RA remains unclear, pro-inflammatory cytokines such as interleukin (IL)-17 are associated with RA pathogenesis [3, 4]. In RA, IL-17 releases CD4+ T cells (helper T 17 [Th17]), which induce an inflammatory response that causes acute symptoms [5]. Mice with collagen-induced arthritis (CIA) are widely used as an RA disease model [6]. In the present study, we performed clinical and histological analyses using CIA mice to explore RA pathology.

Coenzyme Q10 (CoQ10), which is also known as ubiquinone, is a lipid containing 1,4-benzoquinone and a side chain with 10 isoprenyl subunits in its tail [7]; it is an oil-soluble antioxidant found in most eukaryotic cells [8]. In mitochondria, CoQ10 plays a critical role in producing adenosine triphosphate (ATP) via the oxidative phosphorylation pathway [9, 10]. Recently, CoQ10 has been reported to have anti-inflammatory functions and exhibit therapeutic effects for immune disorders [11, 12]. Some studies have demonstrated therapeutic effects of CoQ10 against RA through the regulation of immune process factors such as tumor necrosis factor (TNF)-α and IL-6 [13, 14]. Our previous studies showed that CoQ10 inhibited autoimmune disease pathogenesis [15, 16]. We also demonstrated that CoQ10 suppresses Th17 cells in experimental autoimmune arthritis mice via inhibition of the signal transducer and activator of transcription (STAT3) signaling pathway [17, 18].

Thus, CoQ10 confers various benefits against immune diseases; however, it is a water-insoluble component, such that its absorption in the small intestine is inefficient [19]. Therefore, we used liposome/gold hybrid nanoparticles encoded with CoQ10 (LGNP-CoQ10) to improve CoQ10 absorption [20]. This hybrid system is dependent on temperature, pH, and light activation and therefore has site-specific drug delivery functions and is safe in cells [21]. Some studies have demonstrated its therapeutic effects on immune cells such as dendritic cells and macrophages [22, 23].

In the present study, we hypothesized that LGNP-CoQ10 suppresses the pathology of experimental autoimmune arthritis. We established liposomes to treat CIA mice with different levels of CoQ10 (no CoQ10, CoQ10 alone, and CoQ10/gold hybrid nanoparticles) for 10 weeks. We then examined whether these liposomes had therapeutic effects in CIA mice.

2. Materials and methods

2.1 Animals

We maintained 7-week-old male DBA/1J mice (Orient Bio, Gyeonggi-do, Korea) under specific pathogen-free conditions. The mice were fed standard laboratory mouse chow (Ralston Purina, St. Louis, MO, USA) and water ad libitum; they were housed (five mice per cage) in a room under controlled temperature (21–22°C) and lighting (12-h light/12-h dark cycle) conditions. The Animal Care Committee of The Catholic University of Korea approved the experimental protocol. All experimental procedures were evaluated and conducted in accordance with the protocols approved by the Animal Research Ethics Committee at the Catholic University of Korea (ID number: 2017-0104-01). All procedures performed in this study followed the ethical guidelines for animal use.

2.2 Formation of LGNP-CoQ10

A chloroform solution containing 500 μg saturated neutral phospholipids (1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]) was dropped into a glass vial. Next, a lipid film was formed by evaporating the chloroform solution under an N2 stream. The film was maintained in a vacuum for longer than 1 h and then hydrated at 55°C by adding 0.5 mL ascorbic acid solution (C6H8O6, 600 mM, pH 5) and 0.5 mL CoQ10 solution. To obtain unilamellar liposomes, as-prepared multilamellar liposomes were extruded through a polycarbonate membrane (pore size: 100 nm) 20 times at 60°C using a mini-extruder. Unilamellar liposomes were purified by centrifugation and washed three times with deionized water to remove residues. Finally, the liposomes encoded with ascorbic acid and CoQ10 were re-suspended using a gold precursor aqueous solution (HAuCl4∙3H2O, tetrachloroauric acid trihydrate, 200 μM) and kept overnight in an agitating incubator at room temperature [24]. The LGNP-CoQ10 structure is shown in Fig 1A.

Fig 1

Formation of liposome/gold nanoparticles encoded with CoQ10 (LGNP-CoQ10).

(A) Structure of the LGNP-CoQ10. (B and C) The cloudy color and ultraviolet-visible (UV-vis) absorbance of CoQ10, CoQ10 liposome, and CoQ10+gold liposome solutions are presented. (D) The morphology of liposomes that contained only CoQ10 and gold nanoparticles + CoQ10 was assessed by transmission electron microscopy (TEM). Scale bars = 50 nm.

2.3 Arthritis induction and treatment

CIA was induced in DBA1/J mice (n = 5). The experiment was performed in triplicate. Type II collagen (CII) was dissolved overnight in 0.1 N acetic acid (4 mg/mL) with gentle rotation at 4°C. Male DBA/1J mice were immunized intra-dermally at the base of the tail with 100 μg chicken CII (Chondrex, Inc., Remosa, WA, USA) in complete Freund’s adjuvant (Chondrex Inc.). In experiments conducted to investigate preventive effects, mice were boosted with 100 μg CII emulsified with incomplete Freund’s adjuvant (Chondrex Inc.), injected intradermally at the base of the tail on day 17 after primary immunization. These arthritis model mice were treated orally with Gold Lipo CoQ10 (0.1 mg/mouse) or CoQ10 (0.1 mg/mouse) starting on day 17 after the first immunization. The mice were examined visually twice weekly for the appearance of arthritis in the peripheral joints. All mice were sacrificed on week 10 for histological analyses of splenocytes and determination of protein expression.

2.4 Clinical assessment of arthritis

Arthritis severity was recorded using the mean arthritis index on a scale of 0 to 4, as follows: (0) no evidence of erythema or swelling; (1) erythema and mild swelling confined to the midfoot (tarsals) or ankle joint; (2) erythema and mild swelling extending from the ankle to the midfoot; (3) erythema and moderate swelling extending from the ankle to the metatarsal joints; and (4) erythema and severe swelling encompassing the ankle, foot, and digits. Arthritis severity was determined as the sum of the scores of all legs, as assessed by two independent observers with no knowledge of the experimental groups.

2.5 Histological analyses

Mouse joint tissues were fixed in 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA), decalcified in histological decalcifying agent (Calci-Clear Rapid; National Diagnostics, Atlanta, GA, USA), trimmed, and embedded in paraffin wax. Sections (7 μm) were prepared and stained with hematoxylin (YD Diagnostics, Yongin, Korea), eosin (Muto Pure Chemicals Co., Ltd., Tokyo, Japan), and Safranin O (Sigma-Aldrich). Cartilage damage was scored as described previously [25].

2.6 Immunohistopathological analyses

Joint tissues were first incubated with primary antibodies against IL-1β (R & D Systems, Minneapolis, MN, USA), IL-6 (R & D Systems), TNF-α (R & D Systems), IL-17 (R & D Systems), and RANK ligand (RANKL; R & D Systems) overnight at 4°C. Samples were incubated with a biotinylated secondary antibody, followed by incubation with a streptavidin–peroxidase complex for 1 h. Samples were then developed using chromogen 3,3′-diaminobenzidine (Thermo Scientific, Rockford, IL, USA). The sections were examined using a photomicroscope (Olympus, Tokyo, Japan).

2.7 Confocal microscopy of immunostaining

Spleen tissues were obtained at 10 weeks after the first immunization. Tissues were snap-frozen in liquid nitrogen and stored at –80°C. Tissue sections were fixed in 4% paraformaldehyde and stained with phycoerythrin (PE)-conjugated rat monoclonal anti-CD4, fluorescein isothiocyanate (FITC)-conjugated rat monoclonal anti-IL-17, FITC-conjugated mouse monoclonal anti-pSTAT3 705, and FITC-conjugated mouse monoclonal anti-pSTAT3 727 (all from eBiosciences, San Diego, CA, USA). Stained sections were analyzed microscopically (LSM510Meta; Carl Zeiss, Oberkochen, Germany).

2.8 Cell culture

Splenocytes were prepared from the spleens of normal C57BL/6 mice. Splenocytes were maintained in RPMI1640 medium supplemented with 5% fetal bovine serum (Gibco, Grand Island, NY, USA) and stimulated with anti-CD3 (0.5 μg/mL; BD Biosciences, San Jose, CA, USA) for 3 days and subjected to enzyme-linked immunosorbent assay (ELISA).

2.9 Statistical analyses

Statistical analyses were conducted using the nonparametric Mann–Whitney U test for comparisons between two groups, and one-way analysis of variance (ANOVA) with Bonferroni’s post hoc test for multiple comparisons. We used the GraphPad Prism v. 5.01 software (GraphPad Software Inc., San Diego, CA, USA) for all analyses. The threshold for statistical significance was P < 0.05. All data are presented as means ± standard deviation (SD).

3. Results

3.1 Formation of LGNP-CoQ10

Liposomes encoded with a reducing agent (i.e., ascorbic acid) and coenzyme Q10 (CoQ10) were prepared through the extrusion of multilamellar liposomes (see Methods). To form gold nanoparticles within the liposomes, gold precursor solution was added into the as-prepared liposomes (Fig 1A). The cloudy color of the solution gradually changed to violet over time (Fig 1B). The solution was sampled for ultraviolet-visible absorbance and transmission electron microscopy (TEM) measurements. The absorbance spectrum clearly exhibited a characteristic surface plasmon resonance band at 545 nm (Fig 1C). To characterize the liposome, TEM measurements were performed; TEM images showed round-shaped structures without any ruptures (Fig 1D). Representative TEM images showed nanoparticles surrounded by a lipid layer, indicating the formation of gold nanoparticles within liposomes encoded with CoQ10.

3.2 The pathogenesis of rheumatoid arthritis was suppressed by LGNP-CoQ10 in CIA mice

To determine whether LGNP-CoQ10 had therapeutic effects in CIA mice, liposomes were injected into the mice for 10 weeks. Pathology scores and incidence of arthritis were significantly reduced in CoQ10- and LGNP-CoQ10-injected mice (Fig 2A). Although it was effective in both, the treatment of LGNP-CoQ10 had a higher therapeutic effect on RA. Mouse joint tissues were monitored for tissue disruption following hematoxylin and eosin and Safranin O staining (Fig 2B). Histological analysis showed that the average scores of bone damage, cartilage damage, and inflammation were notably reduced in the LGNP-CoQ10-injected group.

Fig 2

Pathology scores of CoQ10 and LGNP-CoQ10-injected mice.

(A) The arthritis score and incidence of CIA mice in each group are shown. (B) Joint tissues of CIA mice were stained with hematoxylin and eosin as well as Safranin O. *P < 0.05; **P < 0.01. Scale bars = 100 μm.

3.3 Expression of pro-inflammatory cytokines was decreased in joints of LGNP-CoQ10-treated mice

We obtained mouse joint tissues at the end of the experiments. Pro-inflammatory cytokines such as IL-1β, IL-6, IL-17 and TNF-α, and an osteoclast differentiation marker, RANKL, were observed in the joint tissues by immunohistochemistry (Fig 3). The tissue immunohistochemistry images of CoQ10-injected mice showed a significant reduction of the pro-inflammatory cytokines and RANKL. Besides, the joint tissues which were treated the LGNP-CoQ10 were more decreased the pro-inflammatory cytokines and RANKL than only the CoQ10-treated group. This result suggested that the LGNP-CoQ10 system is more effective using CoQ10 alone.

Fig 3

Immunohistochemistry of joint tissues in vehicle-, CoQ10-, and LGNP-CoQ10-injected mice.

*P < 0.05; **P < 0.01; and ***P < 0.001. Scale bars = 100 μm.

3.4 Expression of IL-17 and phosphorylated STAT3 was reduced by LGNP-CoQ10 in spleen CD4+ T cells

After the mice were sacrificed, we obtained spleen tissues and performed immunofluorescence staining (Fig 4). In spleen tissues, Th17 cells were decreased following CoQ10 treatment, and more significantly following LGNP-CoQ10 treatment. Besides, the spleen tissue immunofluorescence images showed a reduction in phosphorylated STAT3 among CoQ10-treated mice. This data suggested that the CoQ10 and LGNP-CoQ10 suppressed the IL-17 producing cells in the spleen tissue.

Fig 4

Immunofluorescence of spleen tissues.

(A and B) Th17 cells and phosphorylated STAT3 expression in the spleens of treatment with vehicle, CoQ10 and LGNP-CoQ10 were detected by confocal microscopy. *P < 0.05; **P < 0.01; and ***P < 0.001. Scale bars = 10 μm.

3.5 IL-17 levels decreased in peripheral blood mononuclear cells following treatment with LGNP-CoQ10

To investigate the effects of CoQ10 and LGNP-CoQ10 treatment in reducing IL-17 expression, we treated human peripheral blood mononuclear cells (PBMCs) with CoQ10 and LGNP-CoQ10 under anti-CD3 conditions. IL-17 levels in the culture supernatants were detected by ELISA, and found to be significantly decreased in LGNP-CoQ10-treated PBMCs (Fig 5).

Fig 5

IL-17 levels were detected by ELISA in human peripheral blood mononuclear cells (PBMC) in anti-CD3 conditions.

The isolated PBMC was seeded and treated the 0.5μM of CoQ10 and LGNP-CoQ10 for 3 days respectively. **P < 0.01 and ***P < 0.001.

4. Discussion

Although CoQ10 has been studied as a powerful antioxidant, there is accumulating evidence that it has anti-inflammatory functions. In the present study, we demonstrated that CoQ10 has anti-inflammatory effects on experimental autoimmune arthritis. We also investigated the therapeutic functions of LGNP-CoQ10.

In our previous studies, we demonstrated that CoQ10 has anti-inflammatory functions through the suppression of Th17 cells [15-17]. In particular, we showed that CoQ10 inhibited Th17 cells through the suppression of phosphorylated STAT3 (p-STAT3) production [18]; p-STAT3 is the activated form of STAT3, and is known to increase levels of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β [26].

CoQ10 confers various benefits and is found in some foods such as sardines, mackerels, and green leafy vegetables including soybeans, peanuts, and beef liver. Therefore, humans typically ingest 3–5 mg of CoQ10 per day in food [27]. Despite the intake of high doses of CoQ10, its absorption efficiency in the gastrointestinal tract is poor [28]. CoQ10 has a biopharmaceutics classification system (BCS) index of 2 or 4, which are typical values for low-solubility drugs [29]. Therefore, we applied a gold/liposome nanoparticle hybrid system to improve CoQ10 absorption in this study.

We established liposome structures including CoQ10, as well as CoQ10/gold nanoparticle hybrids. Our previous studies demonstrated that the LGNP system has higher absorption efficiency [30, 31]. LGNP system facilitates endocytosis by wrapping the particles in a phospholipid bilayer which is the same with the cell’s surface, helping the cells absorb the particles. These liposomes were injected orally in CIA mice. We found that CoQ10 or CoQ10/gold nanoparticles suppressed the pathogenesis of experimental RA in the animal model. RA pathology was significantly decreased in LGNP-CoQ10-treated mice; however, there were no significant differences in the group treated with CoQ10 alone. Moreover, inflammation, bone damage, and cartilage damage scores were notably reduced in the LGNP-CoQ10-injected mice. Pro-inflammatory cytokines (IL-1β, IL-6, IL-17, TNF-α, and RANKL) were decreased in CIA mice treated with LGNP-CoQ10. Interestingly, Th17 cells decreased in the spleen tissue of CoQ10/gold nanoparticle-injected mice. We also investigated p-STAT3 levels in the spleen, and found that p-STAT3 was reduced in CD4+ T cells. A previous study showed that the increase of ROS promotes Th17 differentiation and IL-17 production through the activation of RORγt and STAT3 pathway [32]. CoQ10 is a reactive oxygen species (ROS) scavenger. Therefore, CoQ10 can directly or indirectly regulate Th17 and IL-17 as ROS scavengers through the STAT3 pathway. Together, these data suggest that the combination of CoQ10 and gold nanoparticles has more effective anti-inflammatory effects than liposome structures containing only CoQ10.

The results of the present study demonstrate that CoQ10 treatment suppressed the pathogenesis of RA in CIA mice. In particular, LGNP-CoQ10 reduced IL-17 levels through the inhibition of p-STAT3. Together, these results show that LGNP-CoQ10 has therapeutic potential for treating RA.

5 Conclusion

The hybrid nanoparticles encoded with Coenzyme Q10 (LGNP-CoQ10) has more effective functions than CoQ10 in rheumatoid arthritis. LGNP-CoQ10 has therapeutic potential for the treatment of rheumatoid arthritis. It was reduced IL-17 level through the inhibition of phosphorylated STAT3.

8 Sep 2020

PONE-D-20-25707

Liposome/gold hybrid nanoparticle encoded with CoQ10 (LGNP-CoQ10) suppressed rheumatoid arthritis via STAT3/Th17 targeting

PLOS ONE

Dear Dr. Cho,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please address all critiques raised by the reviewers. Particularly, reviewer #1 raised a few critical comments regarding the role of the nanoparticle on Th17 cell responses. Other minor comments should also be addressed in the revised manuscript.

Please submit your revised manuscript by Oct 23 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Yeonseok Chung

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In this manuscript, authors demonstrated the enhanced anti-inflammatory effect of LGNP-CoQ10 compared to CoQ10 in collagen induced arthritis model (CIA). Oral administration of LGNP-CoQ10 ameliorated the pathogenesis of CIA by decreasing inflammatory cytokines including IL-1β, IL-6, IL-17, and TNF-α. The therapeutic effect of LGNP-CoQ10 is impressive. However, several concerns should be addressed to convincingly describe the author’s novel findings.

Major points

- The data showed that LGNP-CoQ10 inhibits CIA through IL-17 related pathways. However, it is not clear that LGNP-CoQ10 reduces IL-17 production from CD4 T cells. As authors titled this article that ‘Liposome/gold hybrid nanoparticle encoded with CoQ10 (LGNP-CoQ10) suppressed rheumatoid arthritis via STAT3/‘Th17’ targeting’, please show the LGNP-CoQ10 mediated IL-17 inhibition in CD4 T cells and other IL-17–producing cells.

- How does LGNP-CoQ10 reduces IL-17 levels? For example, LGNP-CoQ10 inhibits induction of IL-17–producing cells or decreases the maintenance of established IL-17–producing cells?

Minor points

- Please describe the meaning of each data more in detail including Figure 3 in the result section.

- Figure 4B is not marked in the Figure 4.

Reviewer #2: This study evaluated the anti-inflammatory effect of CoQ in liposome/gold hybrid nanoparticle (LGNP-CoQ10) in the animal model of rheumatoid arthritis. Although the therapeutic potential of LGNP-CoQ10 against rheumatoid arthritis seems promising according to the results in the study, the current manuscript has too many typos and errors and did not extensively describe or interpret the data. Please find my comments as below.

Materials and Methods

1. In the Confocal microscopy of immunostaining section, please provide the clone name for the antibodies used in the study.

2. In the Cell culture section, C57NL/6? Is this a typo of C57BL/6?

Results

3. In the “Formation of LGNP-CoQ10”, no description about Figure 1A

4. In the “The pathogenesis of rheumatoid arthritis was suppressed by LGNP-CoQ10 in CIA mice”, the authors should compare the results of all tested experimental groups in the figure. They did not describe the result of CoQ10 in Figure 2A. Also, in the last sentence of this paragraph, the authors did not interpret the data of Figure 3.

5. In the “Expression of IL-17 and phosphorylated STAT3…”, there is no B in Figure 4B.

Figures

6. Please add B in Figure 4

7. Please remove A in the figure 5.

Figure legends

8. In the legend of Figure 4, please add CoQ10 in the second sentence.

9. In the legend of Figure 5, please describe the experimental condition in more detail including the addition of CoQ10 and NGNP-CoQ10.

Discussion

10. In the fourth paragraph, the authors demonstrated that “We found that only liposomes containing CoQ10 or CoQ10/gold nanoparticles suppressed the pathogenesis of experimental RA in the animal model.”. Throughout the study except Figure 1, the authors compared LGNP-CoQ10 with CoQ10 alone (or vehicle) but they did not include CoQ10 in liposome as an experimental group. Please make it clear whether CoQ group in the Figure 2-5 means CoQ10 itself or CoQ10 in liposome.

11. Please discuss how LGNP can improve the solubility or absorption of CoQ10 in vivo.

12. Is the effect of CoQ10 on suppression of Stat3 phosphorylation direct or indirect? Please explain the mechanism by which CoQ10 modulate the Stat3 phosphorylation in Th17 cells.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

6 Oct 2020

Reviewer #1: In this manuscript, authors demonstrated the enhanced anti-inflammatory effect of LGNP-CoQ10 compared to CoQ10 in collagen induced arthritis model (CIA). Oral administration of LGNP-CoQ10 ameliorated the pathogenesis of CIA by decreasing inflammatory cytokines including IL-1β, IL-6, IL-17, and TNF-α. The therapeutic effect of LGNP-CoQ10 is impressive. However, several concerns should be addressed to convincingly describe the author’s novel findings.

Major points

- The data showed that LGNP-CoQ10 inhibits CIA through IL-17 related pathways. However, it is not clear that LGNP-CoQ10 reduces IL-17 production from CD4 T cells. As authors titled this article that ‘Liposome/gold hybrid nanoparticle encoded with CoQ10 (LGNP-CoQ10) suppressed rheumatoid arthritis via STAT3/‘Th17’ targeting’, please show the LGNP-CoQ10 mediated IL-17 inhibition in CD4 T cells and other IL-17–producing cells.

� Thank you for your comments. As the reviewer pointed, the authors investigated the population of Th17 using flow cytometry. Although the population of Th17 cells of CoQ10 and LGNP-CoQ10 injected group tended to decrease, however, there were no significant differences. So, we didn’t put the data in the manuscript. Instead of the FACS data, we added the immunofluorescence images of spleen tissues (Figure 4) and serum ELISA data (Figure 5) in this study.

- How does LGNP-CoQ10 reduces IL-17 levels? For example, LGNP-CoQ10 inhibits induction of IL-17–producing cells or decreases the maintenance of established IL-17–producing cells?

� As the reviewer pointed, the accurate mechanism of reduction of IL-17 by LGNP-CoQ10 was not conducted in this paper. However, our previous studies confirmed the Coenzyme Q10 has a therapeutic effect on rheumatoid arthritis through the regulation of IL-17 level (Lee SY et al. A Combination with Probiotic Complex, Zinc, and Coenzyme Q10 Attenuates Autoimmune Arthritis by Regulation of Th17/Treg Balance. J Med Food. 2018; Lee SH et al. Coenzyme Q10 Exerts Anti-Inflammatory Activity and Induces Treg in Graft Versus Host Disease. J Med Food. 2016; Jhun J et al. Combination therapy with metformin and coenzyme Q10 in murine experimental autoimmune arthritis. Immunopharmacol Immunotoxicol. 2016). besides, coenzyme Q10 suppressed the differentiation of Th17 cells and osteoclast, it also inhibited the STAT3 signaling pathway in the autoimmune disease mouse model. (Jhun J et al. Coenzyme Q10 suppresses Th17 cells and osteoclast differentiation and ameliorates experimental autoimmune arthritis mice. Immunol Lett. 2015; Lee SY et al. Coenzyme Q10 Inhibits Th17 and STAT3 Signaling Pathways to Ameliorate Colitis in Mice. J Med Food. 2017.) LGNP-CoQ10 system was used as an improvement process to increase the absorption rate of CoQ10. For this reason, the mechanism for reducing IL-17 by LGNP-CoQ10 is expected to be similar to previous studies.

Minor points

- Please describe the meaning of each data more in detail including Figure 3 in the result section.

� As the reviewer commented, the author added more detail explanation in the manuscript. “We obtained mouse joint tissues at the end of the experiments. Pro-inflammatory cytokines such as IL-1β, IL-6, IL-17 and TNF-α, and an osteoclast differentiation marker, RANKL, were observed in the joint tissues by immunohistochemistry (Figure 3). The tissue immunohistochemistry images of CoQ10-injected mice showed a significant reduction of the pro-inflammatory cytokines and RANKL. Besides, the joint tissues which were treated the LGNP-CoQ10 were more decreased the pro-inflammatory cytokines and RANKL than only the CoQ10-treated group. This result suggested that the LGNP-CoQ10 system is more effective using CoQ10 alone.”

- Figure 4B is not marked in the Figure 4.

� As the reviewer pointed, the author edited the manuscript and the figure 4. “After the mice were sacrificed, we obtained spleen tissues and performed immunofluorescence staining (Figure 4). In spleen tissues, Th17 cells were decreased following CoQ10 treatment, and more significantly following LGNP-CoQ10 treatment. Besides, the spleen tissue immunofluorescence images showed a reduction in phosphorylated STAT3 among CoQ10-treated mice. This data suggested that the CoQ10 and LGNP-CoQ10 suppressed the IL-17 producing cells in the spleen tissue.”

Reviewer #2: This study evaluated the anti-inflammatory effect of CoQ in liposome/gold hybrid nanoparticle (LGNP-CoQ10) in the animal model of rheumatoid arthritis. Although the therapeutic potential of LGNP-CoQ10 against rheumatoid arthritis seems promising according to the results in the study, the current manuscript has too many typos and errors and did not extensively describe or interpret the data. Please find my comments as below.

Materials and Methods

1. In the Confocal microscopy of immunostaining section, please provide the clone name for the antibodies used in the study.

� Thank you for your comments. As the reviewer pointed, the authors added the clone name of antibodies in the manuscript. “Tissue sections were fixed in 4% paraformaldehyde and stained with phycoerythrin (PE)-conjugated rat monoclonal anti-CD4, fluorescein isothiocyanate (FITC)-conjugated rat monoclonal anti-IL-17, FITC-conjugated mouse monoclonal anti-pSTAT3 705, and FITC-conjugated mouse monoclonal anti-pSTAT3 727 (all from eBiosciences, San Diego, CA, USA).”

2. In the Cell culture section, C57NL/6? Is this a typo of C57BL/6?

� As the reviewer pointed, the authors edited the typo in the manuscript. “Splenocytes were prepared from the spleens of normal C57BL/6 mice.”

Results

3. In the “Formation of LGNP-CoQ10”, no description about Figure 1A

� As the reviewer pointed, the authors edited the manuscript. “To form gold nanoparticles within the liposomes, gold precursor solution was added into the as-prepared liposomes (Figure 1A).”

4. In the “The pathogenesis of rheumatoid arthritis was suppressed by LGNP-CoQ10 in CIA mice”, the authors should compare the results of all tested experimental groups in the figure. They did not describe the result of CoQ10 in Figure 2A. Also, in the last sentence of this paragraph, the authors did not interpret the data of Figure 3.

� As the reviewer pointed, the authors edited the manuscript and added more detail explanation. “Pathology scores and incidence of arthritis were significantly reduced in CoQ10- and LGNP-CoQ10-injected mice (Figure 2A). Although it was effective in both, the treatment of LGNP-CoQ10 had a higher therapeutic effect on RA.” and “The tissue immunohistochemistry images of CoQ10-injected mice showed a significant reduction of the pro-inflammatory cytokines and RANKL. Besides, the joint tissues which were treated the LGNP-CoQ10 were more decreased the pro-inflammatory cytokines and RANKL than only the CoQ10-treated group. This result suggested that the LGNP-CoQ10 system is more effective using CoQ10 alone.”

5. In the “Expression of IL-17 and phosphorylated STAT3…”, there is no B in Figure 4B.

� As the reviewer pointed, the authors edited the manuscript and figure. “After the mice were sacrificed, we obtained spleen tissues and performed immunofluorescence staining (Figure 4). In spleen tissues, Th17 cells were decreased following CoQ10 treatment, and more significantly following LGNP-CoQ10 treatment. Besides, the spleen tissue immunofluorescence images showed a reduction in phosphorylated STAT3 among CoQ10-treated mice. This data suggested that the CoQ10 and LGNP-CoQ10 suppressed the IL-17 producing cells in the spleen tissue.”

Figures

6. Please add B in Figure 4

� As the reviewer pointed, the authors edited the Figure 4.

7. Please remove A in the figure 5.

� As the reviewer pointed, the authors edited the Figure 5.

Figure legends

8. In the legend of Figure 4, please add CoQ10 in the second sentence.

� As the reviewer commented, the authors added “CoQ10” in the legend of Figure 4.

9. In the legend of Figure 5, please describe the experimental condition in more detail including the addition of CoQ10 and NGNP-CoQ10.

� As the reviewer pointed, the authors added more detail explanation. “IL-17 levels were detected by ELISA in human peripheral blood mononuclear cells (PBMC) in anti-CD3 conditions. The isolated PBMC was seeded and treated the 0.5µM of CoQ10 and LGNP-CoQ10 for 3 days respectively.”

Discussion

10. In the fourth paragraph, the authors demonstrated that “We found that only liposomes containing CoQ10 or CoQ10/gold nanoparticles suppressed the pathogenesis of experimental RA in the animal model.”. Throughout the study except Figure 1, the authors compared LGNP-CoQ10 with CoQ10 alone (or vehicle) but they did not include CoQ10 in liposome as an experimental group. Please make it clear whether CoQ group in the Figure 2-5 means CoQ10 itself or CoQ10 in liposome.

� We mean it is the CoQ10 exclusive use group. So, the authors edited the manuscript as the reviewer pointed. “We found that CoQ10 or CoQ10/gold nanoparticles suppressed the pathogenesis of experimental RA in the animal model.”

11. Please discuss how LGNP can improve the solubility or absorption of CoQ10 in vivo.

� Our previous studies demonstrated that the liposomal system with gold nanoparticles has higher absorption efficiency (Jin-Ho Lee et al. General and programmable synthesis of hybrid liposome/metal nanoparticles. Sci Adv. 2016; Youngjae Lee et al. Phase transfer-driven rapid and complete ligand exchange for molecular assembly of phospholipid bilayers on aqueous gold nanocrystals. Chem Commun. 2019.). This system facilitates endocytosis by wrapping the particles in a phospholipid bilayer like the cell’s surface, helping the cells to absorb the particles. The authors added the information in the discussion part of the manuscript. “Our previous studies demonstrated that the LGNP system has higher absorption efficiency [30, 31]. LGNP system facilitates endocytosis by wrapping the particles in a phospholipid bilayer which is the same with cell’s surface, helping the cells absorb the particles.”

12. Is the effect of CoQ10 on suppression of Stat3 phosphorylation direct or indirect? Please explain the mechanism by which CoQ10 modulate the Stat3 phosphorylation in Th17 cells.

� As the reviewer pointed, the detailed mechanism of the regulation effect of CoQ10 in Th17 cells is not described in this manuscript. Although our previous studies showed the therapeutic effect of CoQ10 in autoimmune diseases, the accurate mechanism of CoQ10 or LGNP system was not investigated (Jhun J et al. Coenzyme Q10 suppresses Th17 cells and osteoclast differentiation and ameliorates experimental autoimmune arthritis mice. Immunol Lett. 2015; Lee SY et al. Coenzyme Q10 Inhibits Th17 and STAT3 Signaling Pathways to Ameliorate Colitis in Mice. J Med Food. 2017.). For this reason, we are trying to discover the mechanism. We intend to present it in a further study. However, we can infer the process with the following study (Eric V. Dang. Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1. Cell. 2011.). In this study, the increase of ROS promotes Th17 differentiation and IL-17 production through the activation of RORγt and STAT3. Coenzyme Q10 is a ROS scavenger. So, CoQ10 has a regulatory effect on Th17 differentiation and IL-17 production. The authors added the explanation in the manuscript ‘discussion’ part. “A previous study showed that the increase of ROS promotes Th17 differentiation and IL-17 production through the activation of RORγt and STAT3 pathway. CoQ10 is a reactive oxygen species (ROS) scavenger. Therefore, CoQ10 can directly or indirectly regulate Th17 and IL-17 as ROS scavengers through the STAT3 pathway.”

Submitted filename: LGNP-CoQ10 rebuttal letter - 200915.docx

Click here for additional data file.

8 Oct 2020

Liposome/gold hybrid nanoparticle encoded with CoQ10 (LGNP-CoQ10) suppressed rheumatoid arthritis via STAT3/Th17 targeting

PONE-D-20-25707R1

Dear Dr. Cho,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Yeonseok Chung

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

28 Oct 2020

PONE-D-20-25707R1

Liposome/gold hybrid nanoparticle encoded with CoQ10 (LGNP-CoQ10) suppressed rheumatoid arthritis via STAT3/Th17 targeting

Dear Dr. Cho:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Yeonseok Chung

Academic Editor

PLOS ONE